Assessing urinary proteins to differentiate ovarian cancer from non-cancer conditions
Urinary Proteomic Assessment of Ovarian Malignancy and Disease Progression
This study is testing if certain proteins in urine can help tell the difference between women with ovarian cancer and those without it.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 240 (estimated) |
| Ages | 18 Years and up |
| Sex | Female |
| Sponsor | Xiangya Hospital of Central South University Academic / other |
| Locations | 1 site (Changsha, Hunan) |
| Trial ID | NCT06760923 on ClinicalTrials.gov |
What this trial studies
This observational study aims to analyze the urinary proteomic characteristics in women diagnosed with ovarian cancer compared to those without the disease. It seeks to identify differences in urinary protein composition that could assist in diagnosing ovarian cancer and monitoring disease progression. The study will evaluate whether specific urinary protein markers correlate with tumor burden in patients with ovarian cancer. By understanding these proteomic differences, the research hopes to enhance diagnostic and surveillance strategies for ovarian cancer.
Who should consider this trial
Good fit: Ideal candidates for this study are female patients over 18 years old who are undergoing surgical treatment for suspected gynecological conditions.
Not a fit: Patients with a history of malignant tumors, chronic kidney disease, or those currently receiving treatment for their primary disease may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved diagnostic tools and monitoring methods for ovarian cancer, potentially allowing for earlier detection and better management of the disease.
How similar studies have performed: While the approach of using urinary proteomics for cancer diagnosis is being explored, this specific study's methodology and focus on ovarian cancer may provide novel insights into the field.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Female patients in the gynecological ward for surgical treatment. * Initial diagnosis of "pelvic mass" or "malignant ascites" may be considered as ovarian cancer; Or the initial diagnosis of "ovarian cyst", "hydrosalpinx", "uterine fibroids" or "uterine adenomyosis" are considered as gynecological non-malignant diseases. * Over 18 years of age. * Voluntary participation and signing of informed consent. Exclusion Criteria: * Study participants with a prior history of malignant tumors. * Study participants with prior chronic kidney disease or renal insufficiency. * Study participants who have received or are receiving treatment for primary disease. * Study participants whose pathological diagnosis was not clear. Any patient should be excluded from the study if: * Study participants withdraw informed consent and request withdrawal. * Study participants were unable to provide a qualified urine sample. * There are situations in which the researcher considers it necessary to withdraw from the study.
Where this trial is running
Changsha, Hunan
- Xiangya Hosipital of Central South University — Changsha, Hunan, China (Recruiting)
Study contacts
- Study coordinator: Yu Zhang, PhD
- Email: xyzhangyu@csu.edu.cn
- Phone: +86 0731-89753999
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.